A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
There is currently no established treatment for paroxysmal hypertension, but selective
serotonin reuptake inhibitors showed good effect in previous reports. This double-blind,
placebo controlled, prospective multicenter clinical trial will assess the efficacy of
sertraline on cessation or reduction of symptoms of paroxysmal arterial hypertension. 136
patients with documented hypertensive paroxysms with abrupt elevations of blood pressure and
distressful physical symptoms will be randomized in a 1:1 ratio to receive sertraline, 50 mg
daily, or matching placebo as an add-on to their chronic medication. Effect of the treatment
on patient symptoms, office and ambulatory blood pressure and side effects will be evaluated
after 3 months. If proven effective, sertraline might become a standard treatment for this
condition.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital Olomouc
Collaborators:
Brno University Hospital Prerov Hospital St. Anne Thomayer University Hospital Thomayerova Teaching Hospital Tomas Bata Hospital Zlin Tomas Bata Hospital, Czech Republic University Hospital Ostrava Valasske Mezirici Hospital Vsetin Hospital